Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion

Liu, Yang; Wang, Lulu; Song, Qisheng; Ali, Muhammad; Crowe, William N.; Kucera, Gregory L.; Hawkins, Gregory A.; Söker, Shay; Thomas, Karl W.; Miller, Lance D.; Lu, Yong; Bellinger, Christina; Zhang, Wei; Habib, Amyn A.; Petty, W. Jeffrey; Zhao, Dawen

doi:10.1038/s41565-021-01032-w

Cited by 60 publications

(46 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LNPs can be fluorescently labeled with lipophilic tracers (e.g., DiD, DiR) [137] , [152] , [153] , [154] , but this can potentially influence their physicochemical properties and biodistribution. Additionally, lipophilic tracers can leach out the LNPs.…”

Section: Other Techniques That Could Reach Ema/fda Requirementsmentioning

confidence: 99%

Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics

Vervaeke

Borgos

Sanders

et al. 2022

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Section: Other Techniques That Could Reach Ema/fda Requirementsmentioning

confidence: 99%

Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics

Vervaeke

Borgos

Sanders

et al. 2022

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

“…For instance, liposomes supplemented with PS, the most prominent and well‐known “eat‐me” signal, are applied in considerable researches. [ 14 ] However, there are many mechanisms that can inhibit or interfere with PS recognition, such as masking of PS on apoptotic cells by soluble RAGE and annexin A5 or cleaving the PS by neutrophil elastase. [ 8 , 15 ] Furthermore, Suggs and colleagues demonstrated that liposomes modified by the combination of membrane‐associated proteins and PS performed better than PS alone.…”

Section: Introductionmentioning

confidence: 99%

Inhaled Pro‐Efferocytic Nanozymes Promote Resolution of Acute Lung Injury

Zhang

et al. 2022

Advanced Science

View full text Add to dashboard Cite

Acute lung injury (ALI) is a significant contributor to the morbidity and mortality of sepsis. Characterized by uncontrolled inflammation and excessive inflammatory cells infiltration in lung, ALI has been exacerbated by impaired efferocytosis (clearance of apoptotic cells by macrophages). Through specific receptor recognition and activation of downstream signaling, efferocytic macrophages promote resolution of inflammation by efficiently engulfing dying cells, avoiding the consequent release of cellular inflammatory contents. Here, inspired by the intrinsic recovery mechanism of efferocytosis, an apoptotic cell membrane (ACM) coated antioxidant nanozyme (AOzyme) is engineered, thus obtaining an inhalable pro‐efferocytic nanozyme (AOzyme@ACM). Notably, AOzyme@ACM can efficiently increase apoptotic cell removal by combing enhanced macrophages recognition of “eat me” signals through apoptotic body mimicking and scavenge of intracellular excessive reactive oxygen species (ROS), a significant barrier for efferocytosis. AOzyme@ACM can significantly inhibit inflammatory response, promote pro‐resolving (M2) phenotype transition of macrophage, and alleviate ALI in endotoxemia mice compared with AOzyme group. By addressing the critical factor in the pathogenesis of sepsis‐related ALI through restoring efferocytosis activity, the ACM‐based antioxidant nanozyme in this study is envisioned to provide a promising strategy to treat this complex and challenging disease.

show abstract

“…e MPE visually appears bloody or turbid amber. Traditional treatment techniques for MPE include intracavity infusion, chemotherapy, biological therapy, puncture, drainage, and others [9][10][11]. Although they have been widely used in clinical practice, the curative effect is not satisfactory because patients with such relapses are usually in poor general condition and poorly tolerated to treatment.…”

Section: Introductionmentioning

confidence: 99%

Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

Hou

Liu³

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. To investigate the clinical efficacy and safety of albumin paclitaxel combined with intrapleural bevacizumab + lobaplatin for patients with non-squamous non-small cell lung cancer (NS-NSCLC) with malignant pleural effusion (MPE) and analyze prognostic factors. Methods. A total of 126 NS-NSCLC patients were included in the study. Control group with 64 cases received intrapleural infusion of lobaplatin + intravenous albumin paclitaxel, and treatment group with 62 cases received additional intrapleural bevacizumab perfusion. Analysis was performed by collecting data about MPE, progression-free survival (PFS), overall survival (OS), and scores of quality of life. Results. In the treatment and control groups, objective response rate (ORR) was 51.6% and 31.3% (χ2 = 5.39, P = 0.02 ), and disease control rate (DCR) was 91.9% and 71.9% (χ2 = 8.49, P = 0.004 ), respectively. The main adverse reactions (≥grade 3) in the treatment group were thrombocytopenia, peripheral neurotoxicity, proteinuria, neutropenia, and nausea/vomiting, and in the control group, they were weakness, nausea/vomiting, anemia, and peripheral neurotoxicity. In the control and treatment groups, the median PFS was 6.2 (95% confidence interval (CI): 5.86–6.56) and 5.1 (95% CI: 4.956–5.191), and the median OS was 14.4 (95% CI: 12.681–16.113) and 10.6 months (95% CI: 8.759–12.391). The score of quality of life for treated patients was significantly higher than those before treatment and the control group, and the parameters included general health status (GH), role physical (RP), body pain (BP), social function (SF), and vitality (VT); pH, CD4+/CD8+ values, and vascular endothelial growth factor (VEGF) in the pleural effusion significantly affected the PFS and OS ( P < 0.05 ). Bevacizumab administration in patients with bloody pleural effusion did not increase the risk of pleural hemorrhage. Conclusion. The combination of albumin paclitaxel and intrapleural bevacizumab + lobaplatin is effective and may reverse the adverse events in patients with NS-NSCLC and MPE. The change of CD4+/CD8+ ratio before and after treatment is an independent and prognostic factor for patients with NS-NSCLC and MPE.

show abstract

Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion

Cited by 60 publications

References 54 publications

Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics

Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics

Inhaled Pro‐Efferocytic Nanozymes Promote Resolution of Acute Lung Injury

Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About